ArticleAdvanced functional materials2015
Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.
Open access · greenAbstract read
In one paragraph
Article in Advanced functional materials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 188 citations in OpenAlex.
- Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Tunable PEGylation platform for efficient siRNA delivery using mesoporous silica nanoparticles.Journal of biological engineering · 2026Article
- Interpreting the Theranostic Applications of Alumina and Silica Substrates in Cancer.Molecules (Basel, Switzerland) · 2026Review
- Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy.Advanced healthcare materials · 2025Review
- Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers · 2025Review
- Evaluation of anticancer efficacy of survivin si-RNA functionalized combined drug-loaded mesoporous silica nanoparticles in a lung cancer mouse model.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Precision Nanomedicine for Cancer: Innovations, Strategies, and Translational Challenges.OncoTargets and therapy · 2025Review
- Nanotechnology-driven synergy in cardio-oncology: enhancing tumor suppression and reducing cardiotoxicity.Frontiers in pharmacology · 2025Review
- Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Advances in Immunomodulatory Mesoporous Silica Nanoparticles for Inflammatory and Cancer Therapies.Biomolecules · 2024Review
- Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.Applied biochemistry and biotechnology · 2024Review
- The landscape of nanoparticle-based siRNA delivery and therapeutic development.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.Therapeutic delivery · 2024Review
- Nanomedicine in cancer therapy.Signal transduction and targeted therapy · 2023Review
- Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification.Bioengineering (Basel, Switzerland) · 2023Article
- Non-viral gene therapy using RNA interference with PDGFR-α mediated epithelial-mesenchymal transformation for proliferative vitreoretinopathy.Materials today. Bio · 2023Article
- Cell- and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy.Frontiers in pharmacology · 2023Review
- Exploitation of High Tumour GSH Levels for Targeted siRNA Delivery in Rhabdomyosarcoma Cells.Biomolecules · 2022Article
- Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.Nature communications · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Worapol NgamcherdtrakulDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Jingga MorryDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Shenda GuDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
David J CastroDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Shaun M GoodyearDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Thanapon SangvanichDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Moataz M RedaDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Richard LeeDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Samuel A MihelicDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Brandon L BeckmanDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Zhi HuDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Joe W GrayDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Wassana YantaseeDepartment of Biomedical Engineering, Oregon Health & Science University 3303 SW Bond Ave, Portland, OR 97239.
Oregon Health & Science University · USPDX Pharmaceuticals (United States) · US
Funding
Systems-Based Predictions of Responses to Cancer TherapyU54CA112970 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI SPELLMAN, PAUL T. · 2004 to 2014
$27.1MNephrogenic Systemic Fibrosis (NSF): A Rodent Model for Therapeutic InterventionR01GM089918 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI YANTASEE, WASSANA · 2010 to 2013
$1.8MIron functionalized silica as oral phosphate binder to treat hyperphosphatemiaR41DK094571 · NIDDK · PDX PHARMACEUTICALS, INC. · PI YANTASEE, WASSANA · 2012 to 2012
$300kNCI NIH HHS HHSN261201300078CNCI NIH HHS U54 CA112970NIDDK NIH HHS R41 DK094571NIGMS NIH HHS R01 GM089918
Abstract
PubMed holds no abstract for this paper.
Indexed as
cancer nanomedicineHER2+ breast cancermesoporous silica nanoparticlessiRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.